FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Ekterly is the first and only oral on-demand therapy for treating attacks associated with hereditary angioedema – – DRI Healthcare is entitled to a ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

Another Rock Island County Sheriff’s Office deputy said he intends to run for sheriff in 2026. Timothy Gillette, a 28-year ...

Despite the many warnings by law enforcement — reinforced by this newspaper — to be wary of anyone purporting to act in your best interests, egregious examples of violations of that trust continue ...

Around 5:30 p.m., troopers were sent to a report of a single motorcycle crash where Megan Bouchard, 25, the rider, was on a ...